Medicaid Prior Authorization and Discontinuation of Buprenorphine

The authors investigate how Medicaid's utilization management policies, specifically prior authorization (PA), affect the duration of buprenorphine treatment episodes for opioid use disorder. Their analysis of national prescription claims data reveals that buprenorphine discontinuation rates are high across all Medicaid plans, with a notable decline in treatment continuation observed within the first three months, particularly among managed care organization (MCO) plans with PA. The findings suggest a need for further research into additional insurer policies that may impact treatment adherence.